Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists

INKT - MiNK Therapeutics, Inc. Stock Price, Fair Value and News

$12.06-0.60 (-4.74%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

INKT Price Action

Last 7 days

-18.1%

Last 30 days

65.7%

Last 90 days

71.6%

Trailing 12 Months

48.9%

INKT Stock Price

INKT RSI Chart

NovDec2025FebMarAprMayJunJulAug020406080100

INKT Valuation

Market Cap

48.1M

Price/Earnings (Trailing)

-4.94

Price/Sales (Trailing)

10.12

Price/Free Cashflow

-5.75

INKT Price/Sales (Trailing)

2025FebMarAprMayJunJulAug010203040

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

INKT Fundamentals

INKT Revenue

Revenue (TTM)

5.8M

JulAugSepOctNovDec5.8M

INKT Earnings

Earnings (TTM)

-9.7M

Earnings Growth (Yr)

27.45%

Earnings Growth (Qtr)

-12.33%

20212022202320242025-35M-30M-25M-20M-15M-10M

INKT Profitability

Return on Equity

-144.14%

Return on Assets

-228.2%

Free Cashflow Yield

-17.38%

INKT Investor Care

Shares Dilution (1Y)

14.77%

Diluted EPS (TTM)

-2.51

Revenue Breakdown

As of: Dec 31, 2024
Total
TotalValuePercent

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240005.8M
Get all data in R, Python etc through our Historical Stock Data APIs

About MiNK Therapeutics, Inc.

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It's product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.
 CEO
 WEBSITEhttps://minktherapeutics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES37

MiNK Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for MiNK Therapeutics, Inc.? What does INKT stand for in stocks?

INKT is the stock ticker symbol of MiNK Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of MiNK Therapeutics, Inc. (INKT)?

As of Fri Aug 08 2025, market cap of MiNK Therapeutics, Inc. is 48.07 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of INKT stock?

You can check INKT's fair value in chart for subscribers.

Is MiNK Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether INKT is over valued or under valued. Whether MiNK Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact MiNK Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INKT.

What is MiNK Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Aug 08 2025, INKT's PE ratio (Price to Earnings) is -4.94 and Price to Sales (PS) ratio is 10.12. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. INKT PE ratio will change depending on the future growth rate expectations of investors.